<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55439">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02039232</url>
  </required_header>
  <id_info>
    <org_study_id>CARBOFIX P CLD PPS1</org_study_id>
    <nct_id>NCT02039232</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the CarboFix Pedicle Screw System</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CarboFix Orthopedics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CarboFix Orthopedics Ltd.</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of CarboFix' Pedicle Screw
      System in the lumbar spine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Fusion success</measure>
    <time_frame>6 months post-operation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Spinal Stenosis</condition>
  <condition>Spinal Curvatures</condition>
  <condition>Tumor</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pedicle screw system</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 18 years old or older.

          2. Confirmation that the physical examination of radiopathy, myelopathy or combination
             is in correlation with the affected level.

          3. Lumbar CT, MRI, or myelography confirms the level of involvement is consistent with
             the subject's examination.

          4. Informed consent given by the subject.

        Exclusion Criteria:

          1. Subject is not eligible for fixation with market-available fixation means.

          2. Familial history NF2.

          3. Acute traumatic spinal injury with or without neurological signs.

          4. Metabolic bone disease.

          5. History of Paget's disease or other osteodystrophies whether acquired or congenital,
             including renal osteodystrophy, hyperthyroidism, hypothyroidism hyperparathyroidism,
             Ehrlers-Danlos-syndrome, osteogenesis imperfecta, achondroplasia, tuberculosis.

          6. History of mental disorder or current psychiatric treatment.

          7. Pregnancy and/or female subjects intending to become pregnant within the expected
             time frame of the study and/or female subjects of child bearing age who do not use
             conventional contraceptive methods.

          8. Immune deficiency disease.

          9. Infection in the location of the operative site, discitis, osteomyelitis, fever
             and/or leukocytosis (as diagnosed based on the results of CBC and ESR tests).

         10. Scoliosis.

         11. Treatment with drugs that may interfere with bone metabolism such as:

               1. Cumulative dose of 150 mg. of Prednisone or equivalent within the last 6 months.

               2. Calcitonin within the past 6 months.

               3. Bisphosphonates for 30 days or more within the last 12 months.

               4. Bone therapeutic doses of fluoride for 30 days or more within the last 12
                  months.

               5. Bone therapeutic doses of vitamin D or Vitamin D metabolites for 30 days or more
                  within the last 6 months.

               6. Treatment by chemotherapy within the last 12 months.

         12. Lack of willingness to make a commitment to return for required follow up visits.

         13. Drug and/or alcohol abuse.

         14. Morbid obesity.

         15. Metal allergies.

         16. Recent use of other investigational drugs or devices (within the past 30 days).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wachsler-Avrahami</last_name>
    <phone>+97299511511</phone>
    <email>hila@carbo-fix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hillel Yafe MC; Herzeliya MC</name>
      <address>
        <city>Hadera; Herzeliya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Curvatures</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
    <mesh_term>Intervertebral Disk Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
